Harvard Bioscience subsidiary sets IPO range

The Harvard Apparatus Regenerative Technology Inc. subsidiary of Harvard Bioscience Inc. (NASDAQ:HBIO) amended its IPO and now plans to sell 1.7 million shares at $10-$12. An $11 price would raise $18.7 million and value the company at $109.5 million. Summer Street and Maxim are underwriters. Harvard Apparatus proposed to raise up to $20 million in the IPO in December. ...